Psychiatric Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Adolescents With Obesity
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11384-11393
DOI: 10.1111/dom.71353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 14.09.2026. Verfasst von Ting-Hui Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Pediatric Obesity, Anti-Obesity Agents. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dual GIP/GLP‐1 receptor agonists are increasingly used for adolescent obesity, but concerns persist regarding psychiatric adverse events, particularly suicidality.
Methods
This retrospective cohort study used deidentified electronic health records from the TriNetX Global Collaborative Network. Adolescents with overweight or obesity were included. New users of semaglutide, liraglutide, or tirzepatide were compared with those receiving lifestyle interventions. Cohorts were balanced using propensity score matching. The primary outcome was suicide‐related events (suicidal ideation or suicide attempt). Secondary outcomes included suicidal ideation, suicide attempt, anxiety, insomnia, depression, and eating disorders, assessed from 30 days to 1095 days after the index date.
Results
After propensity score matching, 9222 adolescents were included in each group. Incretin‐based therapy was associated with lower risks of suicide‐related events (HR, 0.74; 95% CI, 0.57–0.95), suicidal ideation (HR, 0.73; 95% CI, 0.56–0.96), and anxiety (HR, 0.92; 95% CI, 0.84–0.99) compared with lifestyle intervention. No significant differences were observed for suicide attempt, insomnia, depression, or eating disorders. Risk reductions were significant among female adolescents (HR, 0.61; 95% CI, 0.46–0.82) and those without Type 2 diabetes (HR, 0.63; 95% CI, 0.47–0.85), but not among males or those with Type 2 diabetes. Sensitivity analyses supported the primary findings.
Conclusions
Among adolescents with obesity, incretin‐based therapy was not associated with increased psychiatric risk and was associated with lower risks of suicide‐related events, suicidal ideation, and anxiety compared with lifestyle intervention. Although a lower risk was observed compared with lifestyle intervention, this finding should be interpreted cautiously given potential selection bias and the lack of a significant difference in the active‐comparator analysis with metformin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Psychiatry, Chi Mei Hospital, Liouying, Tainan, Taiwan.
- School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
ORCID-Profile: Jheng-Yan Wu, Chih-Cheng Lai
Zitieren
APA
Liu, T. H., Shen, Y. L., Kuo, T. H., Wu, J. Y., Lin, C. H., & Lai, C. C. (2026). Psychiatric Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Adolescents With Obesity. Diabetes, Obesity and Metabolism, 28(12), 11384-11393. https://doi.org/10.1111/dom.71353
Vancouver
Liu TH, Shen YL, Kuo TH, Wu JY, Lin CH, Lai CC. Psychiatric Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Adolescents With Obesity. Diabetes, Obesity and Metabolism. 2026;28(12):11384-11393. doi:10.1111/dom.71353
BibTeX
@article{Liu2026,
author = {Liu, Ting-Hui and Shen, Yang-Li and Kuo, Tien-Hsiang and Wu, Jheng-Yan and Lin, Chien-Ho and Lai, Chih-Cheng},
title = {Psychiatric Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Adolescents With Obesity},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11384--11393},
doi = {10.1111/dom.71353}
}
EUVIMED